-
1
-
-
84957709696
-
Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside
-
Mudaliar, S., Polidori, D., Zambrowicz, B., Henry, R.R., Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 38 (2015), 2344–2353.
-
(2015)
Diabetes Care
, vol.38
, pp. 2344-2353
-
-
Mudaliar, S.1
Polidori, D.2
Zambrowicz, B.3
Henry, R.R.4
-
2
-
-
84994180780
-
Empagliflozin and progression of kidney disease in type 2 diabetes
-
Wanner, C., Inzucchi, S.E., Lachin, J.M., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
-
(2016)
N Engl J Med
, vol.375
, pp. 323-334
-
-
Wanner, C.1
Inzucchi, S.E.2
Lachin, J.M.3
-
3
-
-
85037667185
-
Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
-
Available at: Accessed June 9, 2017
-
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Available at: https://www.fda.gov/downloads/Drugs/…/Guidances/ucm071627.pdf, 2008 Accessed June 9, 2017.
-
(2008)
-
-
-
4
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman, B., Wanner, C., Lachin, J.M., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
-
5
-
-
84975853831
-
CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis
-
Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
-
(2016)
Diabetes Care
, vol.39
, pp. 1108-1114
-
-
Ferrannini, E.1
Mark, M.2
Mayoux, E.3
-
6
-
-
84975840750
-
Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis
-
Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
-
(2016)
Diabetes Care
, vol.39
, pp. 1115-1122
-
-
Mudaliar, S.1
Alloju, S.2
Henry, R.R.3
-
7
-
-
84980320178
-
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications
-
Heerspink, H.J., Perkins, B.A., Fitchett, D.H., Husain, M., Cherney, D.Z., Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications. Circulation 134 (2016), 752–772.
-
(2016)
Circulation
, vol.134
, pp. 752-772
-
-
Heerspink, H.J.1
Perkins, B.A.2
Fitchett, D.H.3
Husain, M.4
Cherney, D.Z.5
-
8
-
-
84983591995
-
Glucagon and heart in type 2 diabetes: new perspectives
-
Ceriello, A., Genovese, S., Mannucci, E., Gronda, E., Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol, 15, 2016, 123.
-
(2016)
Cardiovasc Diabetol
, vol.15
, pp. 123
-
-
Ceriello, A.1
Genovese, S.2
Mannucci, E.3
Gronda, E.4
-
9
-
-
85025064312
-
Dapagliflozin attenuates diabetic cardiomyopathy and the activation of the NLRP3/ASC inflammasome in mice with type-2 diabetes: a glucose-lowering and SGLT-2 independent effect
-
Paper presented at: ACC 66th Annual Scientific Sessions and Expo; March 17, Washington, DC. Abstract 1162-244
-
Ye Y, Bajaj M, Birnbaum Y. Dapagliflozin attenuates diabetic cardiomyopathy and the activation of the NLRP3/ASC inflammasome in mice with type-2 diabetes: a glucose-lowering and SGLT-2 independent effect. Paper presented at: ACC 66th Annual Scientific Sessions and Expo; March 17, 2017; Washington, DC. Abstract 1162-244.
-
(2017)
-
-
Ye, Y.1
Bajaj, M.2
Birnbaum, Y.3
-
10
-
-
85045782665
-
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: a systematic review
-
[Published correction appears in Cardiol Ther 2016;5:169.]
-
Kalra, S., Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: a systematic review. Cardiol Ther 5 (2016), 161–168 [Published correction appears in Cardiol Ther 2016;5:169.].
-
(2016)
Cardiol Ther
, vol.5
, pp. 161-168
-
-
Kalra, S.1
-
11
-
-
84964507777
-
SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
-
[Published correction appears in Diabetologia 2016;59:1573–4.]
-
Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339 [Published correction appears in Diabetologia 2016;59:1573–4.].
-
(2016)
Diabetologia
, vol.59
, pp. 1333-1339
-
-
Sattar, N.1
McLaren, J.2
Kristensen, S.L.3
Preiss, D.4
McMurray, J.J.5
-
12
-
-
85019611136
-
Novel diabetes drugs and the cardiovascular specialist
-
Sattar, N., Petrie, M.C., Zinman, B., Januzzi, J.L. Jr., Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol 69 (2017), 2646–2656.
-
(2017)
J Am Coll Cardiol
, vol.69
, pp. 2646-2656
-
-
Sattar, N.1
Petrie, M.C.2
Zinman, B.3
Januzzi, J.L.4
-
13
-
-
84988649876
-
Established and emerging roles of biomarkers in heart failure clinical trials
-
e002528
-
Ibrahim, N.E., Gaggin, H.K., Konstam, M.A., Januzzi, J.L. Jr., Established and emerging roles of biomarkers in heart failure clinical trials. Circ Heart Fail, 9, 2016 e002528.
-
(2016)
Circ Heart Fail
, vol.9
-
-
Ibrahim, N.E.1
Gaggin, H.K.2
Konstam, M.A.3
Januzzi, J.L.4
-
14
-
-
84990052413
-
Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis
-
Willeit, P., Kaptoge, S., Welsh, P., et al., for the Natriuretic Peptides Studies Collaboration. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol 4 (2016), 840–849.
-
(2016)
Lancet Diabetes Endocrinol
, vol.4
, pp. 840-849
-
-
Willeit, P.1
Kaptoge, S.2
Welsh, P.3
-
15
-
-
85017227814
-
Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) trial
-
Cavender, M.A., White, W.B., Jarolim, P., et al. Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) trial. Circulation 135 (2017), 1911–1921.
-
(2017)
Circulation
, vol.135
, pp. 1911-1921
-
-
Cavender, M.A.1
White, W.B.2
Jarolim, P.3
-
16
-
-
85019737787
-
Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
-
Ferrannini, E., Baldi, S., Frascerra, S., et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 40 (2017), 771–776.
-
(2017)
Diabetes Care
, vol.40
, pp. 771-776
-
-
Ferrannini, E.1
Baldi, S.2
Frascerra, S.3
-
17
-
-
84880850027
-
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
-
Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 853-862
-
-
Lambers Heerspink, H.J.1
de Zeeuw, D.2
Wie, L.3
Leslie, B.4
List, J.5
-
18
-
-
84994910800
-
Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed type 2 diabetes
-
Wang, Y., Xu, L., Yuan, L., et al. Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed type 2 diabetes. Diabet Med 33 (2016), 1732–1736.
-
(2016)
Diabet Med
, vol.33
, pp. 1732-1736
-
-
Wang, Y.1
Xu, L.2
Yuan, L.3
-
19
-
-
84880543926
-
Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial
-
Bode, B., Stenlöf, K., Sullivan, D., Fung, A., Usiskin, K., Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 41 (2013), 72–84.
-
(2013)
Hosp Pract
, vol.41
, pp. 72-84
-
-
Bode, B.1
Stenlöf, K.2
Sullivan, D.3
Fung, A.4
Usiskin, K.5
-
20
-
-
84964240560
-
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes
-
Bode, B., Stenlöf, K., Harris, S., et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab 17 (2015), 294–303.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 294-303
-
-
Bode, B.1
Stenlöf, K.2
Harris, S.3
-
21
-
-
85102332811
-
Nonparametric Statistical Methods
-
2nd edition John Wiley & Sons, Inc. New York, NY
-
Hollander, M., Wolfe, D.A., Nonparametric Statistical Methods. 2nd edition, 1999, John Wiley & Sons, Inc., New York, NY.
-
(1999)
-
-
Hollander, M.1
Wolfe, D.A.2
-
22
-
-
84892407436
-
The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes
-
Hillis, G.S., Welsh, P., Chalmers, J., et al. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care 37 (2014), 295–303.
-
(2014)
Diabetes Care
, vol.37
, pp. 295-303
-
-
Hillis, G.S.1
Welsh, P.2
Chalmers, J.3
-
23
-
-
84923448295
-
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials
-
Inzucchi, S.E., Zinman, B., Wanner, C., et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12 (2015), 90–100.
-
(2015)
Diab Vasc Dis Res
, vol.12
, pp. 90-100
-
-
Inzucchi, S.E.1
Zinman, B.2
Wanner, C.3
-
24
-
-
84991712516
-
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
-
Baartscheer, A., Schumacher, C.A., Wüst, R.C., et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 60 (2017), 568–573.
-
(2017)
Diabetologia
, vol.60
, pp. 568-573
-
-
Baartscheer, A.1
Schumacher, C.A.2
Wüst, R.C.3
-
25
-
-
85017099681
-
Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
-
[E-pub ahead of print] Apr 8
-
Shi, X., Verma, S., Yun, J., et al. Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?. Mol Cell Biochem, 2017 Apr 8 [E-pub ahead of print].
-
(2017)
Mol Cell Biochem
-
-
Shi, X.1
Verma, S.2
Yun, J.3
-
26
-
-
84914154997
-
Effect of the sodium glucose co-transporter 2 inhibitor, canagliflozin, on plasma volume in patients with type 2 diabetes mellitus
-
Sha, S., Polidori, D., Heise, T., et al. Effect of the sodium glucose co-transporter 2 inhibitor, canagliflozin, on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 16 (2014), 1087–1095.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 1087-1095
-
-
Sha, S.1
Polidori, D.2
Heise, T.3
-
27
-
-
84883591288
-
Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk
-
Glick, D., DeFilippi, C.R., Christenson, R., Gottdiener, J.S., Seliger, S.L., Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk. J Am Coll Cardiol HF 1 (2013), 353–360.
-
(2013)
J Am Coll Cardiol HF
, vol.1
, pp. 353-360
-
-
Glick, D.1
DeFilippi, C.R.2
Christenson, R.3
Gottdiener, J.S.4
Seliger, S.L.5
-
28
-
-
84870346842
-
Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study
-
Coglianese, E.E., Larson, M.G., Vasan, R.S., et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 58 (2012), 1673–1681.
-
(2012)
Clin Chem
, vol.58
, pp. 1673-1681
-
-
Coglianese, E.E.1
Larson, M.G.2
Vasan, R.S.3
-
29
-
-
84955755338
-
Renal effects of canagliflozin in type 2 diabetes mellitus
-
Perkovic, V., Jardine, M., Vijapurkar, U., Meininger, G., Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin 31 (2015), 2219–2231.
-
(2015)
Curr Med Res Opin
, vol.31
, pp. 2219-2231
-
-
Perkovic, V.1
Jardine, M.2
Vijapurkar, U.3
Meininger, G.4
-
30
-
-
84880924263
-
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—a randomized placebo-controlled trial
-
Neal, B., Perkovic, V., de Zeeuw, D., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—a randomized placebo-controlled trial. Am Heart J 166 (2013), 217–223.e11.
-
(2013)
Am Heart J
, vol.166
, pp. 217-223.e11
-
-
Neal, B.1
Perkovic, V.2
de Zeeuw, D.3
-
31
-
-
85013890365
-
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial
-
Neal, B., Perkovic, V., Matthews, D.R., et al., for the CANVAS-R Trial Collaborative Group. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 19 (2017), 387–393.
-
(2017)
Diabetes Obes Metab
, vol.19
, pp. 387-393
-
-
Neal, B.1
Perkovic, V.2
Matthews, D.R.3
-
32
-
-
85020470639
-
Optimizing the analysis strategy for the CANVAS Program—a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials
-
Neal, B., Perkovic, V., Mahaffey, K.W., et al., for the CANVAS Program Collaborative Group. Optimizing the analysis strategy for the CANVAS Program—a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 19 (2017), 926–935.
-
(2017)
Diabetes Obes Metab
, vol.19
, pp. 926-935
-
-
Neal, B.1
Perkovic, V.2
Mahaffey, K.W.3
-
33
-
-
85023777061
-
Canagliflozin and cardiovascular and renal events in type 2 diabetes
-
[E-pub ahead of print] Jun 12
-
Neal, B., Perkovic, V., Mahaffey, K.W., et al., for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017 Jun 12 [E-pub ahead of print].
-
(2017)
N Engl J Med
-
-
Neal, B.1
Perkovic, V.2
Mahaffey, K.W.3
|